| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d160aeee278e57d6e251c4a98a19b0e6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2871
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2821
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2835
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7028
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5088 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
2016-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c297cdd9e024ca4b48dfccfd3e409db
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a64b65c0266ef77ee52a0e8fcc06c76 |
| publicationDate |
2018-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9877979-B2 |
| titleOfInvention |
Method of treating neurological conditions with oleandrin |
| abstract |
A method of treating neurological condition in a subject by administration of a cardiac glycoside is provided. Alzheimer's disease, Huntington's disease or stroke are treated by administering a therapeutically effective amount of cardiac glycoside to a subject. The cardiac glycoside can be present in a dosage form. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10596186-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11007239-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10980852-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11123387-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10702567-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11324789-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021201903-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10729735-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10874704-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11013776-B2 |
| priorityDate |
2010-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |